Molecular characterization and clinical epidemiology of HCV in District Dir (Lower), Pakistan

  • Sami Ullah
  • Muhammad Akram Khan
  • Shafiq Ur Rahman
  • Imran Khan
  • Fazal Akbar
  • Anshu Babbar
Short Communication
  • 7 Downloads

Abstract

With about 200 million infections globally, Hepatitis C virus (HCV) infection is a major global health threat. The relative prevalence of hepatitis and HCV genotypes/subtypes varies among different geographic regions. Therefore, the present study was conducted to determine the prevalence of hepatitis C and HCV genotypes/subtypes in District Dir (Lower), Pakistan. Blood samples from HCV positive patients were genotyped through multiplex PCR using specific primers for HCV core region. A structured questionnaire was used to obtain information from the patients and data was statistically analyzed for different epidemiological parameters. The molecular evaluation results suggested the prevalence of genotype 3 in this study. The frequency of hepatitis C was found higher in males (P < 0.01). Present study suggests injections received at local clinics as a highly significant mode of HCV transmission to these patients (P < 0.002). These findings might be helpful for clinicians and related health care personnel to assess status of this important disease and highlight the need for more detailed evaluation of this devastating disease in order to frame better treatment strategies.

Keywords

HCV Epidemiology Liver cancer Genotyping Prevalence 

Notes

Acknowledgements

The Authors are thankful to Ms. Nosheen Riaz for her help in sample collection and Mr. Liaqat Ali, Director, Saifi Clinical laboratory, Islamabad in sample processing.

References

  1. 1.
    Hoofnagle JH. Course and outcome of hepatitis C. Hepatology [Internet]. 2002;36:s21–9. http://doi.wiley.com/10.1053/jhep.2002.36227.
  2. 2.
    Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, et al. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect Genet Evol. [Internet]. 2010;10:595–600. http://linkinghub.elsevier.com/retrieve/pii/S1567134810001103.
  3. 3.
    Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. [Internet]. 2009;15:5647–53. http://www.ncbi.nlm.nih.gov/pubmed/19960560.
  4. 4.
    Ali A, Ahmed H, Idrees M. Molecular epidemiology of Hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan. Virol J. [Internet]. 2010;7:203. http://virologyj.biomedcentral.com/articles/10.1186/1743-422X-7-203.
  5. 5.
    Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis. [Internet]. 2016;16:163. http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1488-0.
  6. 6.
    Turhan V, Ardic N, Eyigun CP, Avci IY, Sengul A, Pahsa A. Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. Chin Med J. (Engl). [Internet]. 2005;118:1392–4. http://www.ncbi.nlm.nih.gov/pubmed/16157037.
  7. 7.
    Youn J-W, Park S-H, Cho JH, Sung YC. Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA Immunization. J Virol. [Internet]. 2003;77:11596–602. http://jvi.asm.org/cgi/doi/10.1128/JVI.77.21.11596-11602.2003.
  8. 8.
    Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama [Internet]. 2001;55:133–59. http://www.ncbi.nlm.nih.gov/pubmed/11434427.
  9. 9.
    Helbling B, Stamenic I, Viani F, Gonvers J-J, Dufour J-F, Reichen J, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology [Internet]. 2002;35:447–54. http://www.ncbi.nlm.nih.gov/pubmed/11826422.
  10. 10.
    Hoofnagle JH, Di Bisceglie AM, Shindo M. Antiviral therapy of hepatitis C—present and future. J Hepatol. [Internet]. 1993;17:S130–6. http://linkinghub.elsevier.com/retrieve/pii/S0168827805804386.
  11. 11.
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (London, England) [Internet]. 1998;352:1426–32. http://www.ncbi.nlm.nih.gov/pubmed/9807989.
  12. 12.
    Takada N, Takase S, Takada A, Date T. Differences in the hepatitis C virus genotypes in different countries. J Hepatol. [Internet]. 1993;17:277–83. http://www.ncbi.nlm.nih.gov/pubmed/8391038.
  13. 13.
    Ullah I, Idrees M, Ahmad H, Ghafoor SU, Ali M, Ali L, et al. Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan. Virol J. [Internet]. 2011;8:16. http://virologyj.biomedcentral.com/articles/10.1186/1743-422X-8-16.
  14. 14.
    Ohno T, Mizokami M, Saleh MG, Orito E, Ohba K-I, Wu R-R, et al. Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients. Arch Virol. [Internet]. 1996;141:1101–13. http://link.springer.com/10.1007/BF01718613.
  15. 15.
    Ahmad W, Ijaz B, Javed F-T, Jahan S, Shahid I, Khan F-M, et al. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol. [Internet]. 2010;16:4321–8. http://www.ncbi.nlm.nih.gov/pubmed/20818816.
  16. 16.
    Jafri SM. Hepatitis C virus—the Pakistani perspective. J Coll Phys. Surg Pak. 2003;13:431.Google Scholar
  17. 17.
    Aziz S, Muzaffar R, Hafiz S, Abbas Z, Zafar MN, Naqvi SA. Helicobacter pylori, hepatitis viruses A, C, E, antibodies and HBsAg—prevalence and associated risk factors in pediatric communities of karachi. J Coll Physicians Surg Pak. 2007;17:195–8.PubMedGoogle Scholar
  18. 18.
    Ilyas M, Ahmad I. Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar Pakistan. Virol J. 2014;11:127.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Aslam M, Aslam J. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J Clin Gastroenterol. [Internet]. 2001;33:407–11. http://www.ncbi.nlm.nih.gov/pubmed/11606859.
  20. 20.
    Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus infections in population. J Coll Physicians Surg Pak. [Internet]. 2004;14:534–6. http://www.ncbi.nlm.nih.gov/pubmed/15353136.
  21. 21.
    Ahmad N, Asgher M, Shafique M, Qureshi JA. An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan. Saudi Med J. [Internet]. 2007;28:390–5. http://www.ncbi.nlm.nih.gov/pubmed/17334466.
  22. 22.
    Idrees M, Lal A, Naseem M, Khalid M (2008) High prevalence of hepatitis C virus infection in the largest province of Pakistan. J Dig Dis 9(2):95–103.  https://doi.org/10.1111/j.1751-2980.2008.00329.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis. [Internet]. 2008;8:69. http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-8-69.
  24. 24.
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. N Engl J Med. [Internet]. 1995;332:1457–63. http://www.nejm.org/doi/abs/10.1056/NEJM199506013322201.
  25. 25.
    McHutchison J. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology [Internet]. 2002;35:688–93. http://doi.wiley.com/10.1053/jhep.2002.31870.
  26. 26.
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. [Internet]. 1996;25:591–8. http://www.ncbi.nlm.nih.gov/pubmed/8938532.
  27. 27.
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Int Med. [Internet]. 1995;122:161–8. http://www.ncbi.nlm.nih.gov/pubmed/7810932.
  28. 28.
    Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. [Internet]. 2008;41:4–8. http://www.ncbi.nlm.nih.gov/pubmed/18327420.
  29. 29.
    Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J, et al. PSG consensus statement on management of hepatitis C virus infection–2003. J Pak Med Assoc. [Internet]. 2004;54:146–50. http://www.ncbi.nlm.nih.gov/pubmed/15129876.
  30. 30.
    Ali SA, Donahue RMJ, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int. J. Infect. Dis. [Internet]. 2009;13:9–19. http://linkinghub.elsevier.com/retrieve/pii/S1201971208014203.
  31. 31.
    Janjua NZ, Nizamy MAM. Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad. J Pak Med Assoc. [Internet]. 2004;54:116–9. http://www.ncbi.nlm.nih.gov/pubmed/15129868.
  32. 32.
    Wazir MS, Mehmood S, Ahmed A, Jadoon HR. Awareness among barbers about health hazards associated with their profession. J Ayub Med Col. Abbottabad. [Internet]. 2008;20:35–8. http://www.ncbi.nlm.nih.gov/pubmed/19385454.
  33. 33.
    Tengan FM, Eluf-Neto J, Cavalheiro NP, Barone AA. Sexual transmission of hepatitis C virus. Rev Inst Med Trop Sao Paulo [Internet]. 2001;43:133–7. http://www.ncbi.nlm.nih.gov/pubmed/11452320.

Copyright information

© Indian Virological Society 2018

Authors and Affiliations

  • Sami Ullah
    • 1
    • 6
  • Muhammad Akram Khan
    • 2
  • Shafiq Ur Rahman
    • 3
  • Imran Khan
    • 4
  • Fazal Akbar
    • 5
  • Anshu Babbar
    • 6
    • 7
  1. 1.Department of BiotechnologyShaheed Benazir Bhutto UniversityDir UpperPakistan
  2. 2.Institute for PathologyPMAS Arid Agriculture UniversityRawalpindiPakistan
  3. 3.Department of PharmacyShaheed Benazir Bhutto UniversityDir UpperPakistan
  4. 4.Heinrich-Heine-Universität DüsseldorfDüsseldorfGermany
  5. 5.Center for Biotechnology and MicrobiologyUniversity of SwatMingoraPakistan
  6. 6.Helmholtz Center for Infection ResearchBrunswickGermany
  7. 7.Department of PaediatricsRWTH University HospitalAachenGermany

Personalised recommendations